Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14931099 | 0.90 | RAB9A (0.47) | RAB9ANAMPTCTSKCTSSALDH1A1 | |
| SCHEMBL14923474 | 0.88 | RAB9A (0.46) | RAB9ANAMPTCTSKCTSSALDH1A1 | |
| SCHEMBL739452 | 0.87 | SUCNR1 (0.49) | RAB9ANAMPTCTSKCTSSCYP3A4 | |
| SCHEMBL739456 | 0.87 | SUCNR1 (0.49) | RAB9ANAMPTCTSKCTSSCYP3A4 | |
| SCHEMBL14923471 | 0.87 | RAB9A (0.45) | RAB9ANAMPTADORA2BCTSKCTSS | |
| SCHEMBL3371141 | 0.86 | RAB9A (0.47) | RAB9ANAMPTCTSKCTSSALDH1A1 | |
| SCHEMBL18511285 | 0.86 | KCNA5 (0.48) | RAB9ANAMPTCTSKCTSSALDH1A1 | |
| SCHEMBL9718033 | 0.84 | RAB9A (0.43) | RAB9ANAMPTCTSKCTSSALDH1A1 | |
| SCHEMBL9608914 | 0.83 | CTSK (0.56) | CTSKCTSSALDH1A1 | |
| SCHEMBL12203909 | 0.83 | CTSK (0.56) | CTSKCTSSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| EP-1915363-A1 | OXOPYRIDYL QUINOLINE AMIDES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018469-A1 | OXOPYRIDYL QUINOLINE AMIDES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | KCNA3, KCNQ3, GPR3 | RAB9A 1964/4885NAMPT 1945/4885ADORA2B 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.